← 返回

Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.

期刊: European journal of heart failure 日期: 2026-05-15 PMID: 42135937 浏览: 39
作者: Sikking, Peisker, Maatz, Lopez-Anguita, Hazebroek, Henkens, Raafs, Heymans, Stroeks, Abdul Hamid, Li, Vicenzetto, Caforio, Brunner-La Rocca, Knackstedt, van Paassen, van Empel, Hubner, Verdonschot, Heymans
Sikking, Peisker, Maatz, Lopez-Anguita, Hazebroek, Henkens, Raafs, Heymans, Stroeks, Hamid, A., Li, Vicenzetto, Caforio, Rocca, B.L., Knackstedt, Paassen, v., Empel, v., Hubner, Verdonschot, & Heymans (2026). Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.. European journal of heart failure.
Sikking, Peisker, Maatz, Lopez-Anguita, Hazebroek, Henkens, et al. Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.. European journal of heart failure. 2026; PMID: 42135937
Sikking, Peisker, Maatz, et al. Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.[J]. European journal of heart failure. 2026.
@article{sikking2026,
  author = {Sikking and Peisker and Maatz and Lopez-Anguita and Hazebroek and Henkens and Raafs and Heymans and Stroeks and Abdul Hamid and Li and Vicenzetto and Caforio and Brunner-La Rocca and Knackstedt and van Paassen and van Empel and Hubner and Verdonschot and Heymans},
  title = {Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.},
  journal = {European journal of heart failure},
  year = {2026},
  note = {PMID: 42135937},
}
TY  - JOUR
AU  - Sikking
AU  - Peisker
AU  - Maatz
AU  - Lopez-Anguita
AU  - Hazebroek
AU  - Henkens
AU  - Raafs
AU  - Heymans
AU  - Stroeks
AU  - Abdul Hamid
AU  - Li
AU  - Vicenzetto
AU  - Caforio
AU  - Brunner-La Rocca
AU  - Knackstedt
AU  - van Paassen
AU  - van Empel
AU  - Hubner
AU  - Verdonschot
AU  - Heymans
TI  - Improved Outcome up to Ten Years after Intravenous Immunoglobulin Therapy in Patients with Dilated Cardiomyopathy.
T2  - European journal of heart failure
PY  - 2026
AN  - PMID:42135937
ER  - 

摘要

A previous trial of intravenous immunoglobulin therapy (IVIg) added to guideline-directed medical therapy (GDMT) in patients with dilated cardiomyopathy (DCM) and cardiac parvovirus-B19 (B19V) persistence showed no improvement of cardiac function at six months follow-up. We investigated whether IVIg confers long-term clinical benefits and analyzed its molecular and cellular effects in cardiac tissue to elucidate the immunomodulatory mechanisms underlying the observed long-term clinical improvement.

AI 智能解读

相关文献

返回分类: 心血管
已选择 0 篇文献